Physician profile
Haroon Yousaf
NPI 1871731364
$7,332.79
in general payments reported to CMS, 2019-2025
15 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $457 · 2021: $224 · 2022: $3,381 · 2023: $879 · 2024: $61.44 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,701.58 | 2019-2024 | Confirm Rx |
| Boston Scientific Corporation | $529.40 | 2019-2025 | Watchman Flx |
| Amgen INC. | $507.37 | 2021-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $366.49 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $230.23 | 2022-2023 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.14 | 2022-2023 | Jardiance |
| Pfizer INC. | $161.50 | 2021-2023 | |
| Bridgebio Pharma, INC. | $144.94 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $133.46 | 2021-2023 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.96 | 2019 | |
| Cardinal Health 200 LLC | $91.79 | 2019 | |
| Medtronic Vascular, INC. | $84.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.55 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $23.04 | 2023 | |
| Medtronic, INC. | $22.85 | 2023 | Micra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Yousaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.